Bain and Bristol Myers Launch $300M Biopharma Immunology Firm

Key Takeaways

Bain Capital raised $300.0M (Series A) from Bain Capital, CPP Investments.
Sector: Biotechnology & Life Sciences.
Geography: United States.

Analysis

Bain Capital and Bristol Myers Squibb have unveiled a new independent biopharmaceutical company dedicated to advancing next-generation immunology treatments nad based in Boston (Massachussetts), with a $300 million Series A funding round led by Bain.

The venture will develop a pipeline of five clinical-stage drug candidates, all licensed from Bristol Myers Squibb. The portfolio includes a late-stage treatment for lupus and a mid-stage therapy for psoriasis, each showing promising results in early trials.

Bristol Myers Squibb will maintain a 20% equity stake in the startup and is entitled to milestone-based payments and royalties tied to future commercial performance. This move allows the pharmaceutical giant to narrow its immunology efforts to immune-resetting innovations while leveraging external development capacity.

The new firm will be led by seasoned biotech executive Daniel Lynch, who will serve as executive chairman and interim CEO. Robert Plenge, Chief Research Officer at Bristol Myers, will join the board, along with partners from Bain Capital.

The initiative has also drawn support from global institutional investors, including the Canada Pension Plan Investment Board (CPP Investments), further underlining confidence in the venture’s therapeutic and commercial potential.

This collaboration reflects a growing trend in the North American biopharma sector, where traditional pharma companies increasingly partner with private equity to accelerate the development of innovative assets through focused, independent platforms.